Last reviewed · How we verify
NCT06238726
Nudging Patients to Increase Shingles Vaccination
NA trial testing Reminder in Shingles in 50,786 participants. Completed in 30 June 2025.
30 June 2025
Quick facts
| Lead sponsor | Geisinger Clinic |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 50,786 |
| Start date | 25 March 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Reminder
Conditions studied
- Shingles — all drugs for Shingles →
- Vaccination Behavior — all drugs for Vaccination Behavior →
- Behavior, Health — all drugs for Behavior, Health →
Sponsor
Geisinger Clinic
Who can join
50 and older, any sex, with Shingles or Vaccination Behavior. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to test whether messages encouraging patients to ask about a Shingrix vaccine at an upcoming appointment will increase Shingrix vaccination rates. The study will also test which of several message versions is most effective.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06238726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Reminder
Trials testing the same drug.
- NCT06566534 — Personalized Nudging to Increase Influenza Vaccinations · NA · completed
- NCT06123936 — Impact on Influenza Vaccination Rates of a Telephone Text Message Recall From the Attending Physician · NA · unknown
- NCT05928689 — Behavioral and Pharmacological Reconsolidation Interference in Misophonia · EARLY_PHASE1 · completed
- NCT05493787 — Nudging Flu Vaccination by Making it Easy for Patients to Schedule a Flu Shot · NA · completed
- NCT05341622 — Mailed FIT Outreach 2022 · NA · completed
Other recruiting trials for Shingles
Currently open trials in the same condition.
- NCT05554068 — Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients · Phase 2 · recruiting
- NCT05596526 — Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients · Phase 4 · recruiting
- NCT05304351 — Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older · Phase 2 · active not recruiting
Other Geisinger Clinic trials
Trials by the same sponsor.
- NCT07197801 — Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Diso · NA · recruiting
- NCT06936709 — Perioperative Colchicine for TKA · Phase 4 · not yet recruiting
- NCT07042477 — Integrated Telemedicine Program Evaluation · NA · recruiting
- NCT07028398 — CMSL Ambulatory Sensitive Condition Nudge Study 2 · NA · recruiting
- NCT06696066 — PEERS Pilot: Peer Recovery Support Program to Support Engagement in Medication for Opioid Use Disorder · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06238726 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Geisinger Clinic
- Last refreshed: 14 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06238726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing